Drug Profile
Research programme: carbon monoxide based therapeutics - Hillhurst Biopharmaceuticals
Alternative Names: HBI 137Latest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Hillhurst Biopharmaceuticals
- Class Anti-inflammatories; Inorganic carbon compounds; Neuroprotectants
- Mechanism of Action Heme oxygenase 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal transplant rejection
- No development reported Brain injuries; Delayed graft function; Inflammation; Multiple sclerosis; Sickle cell anaemia
Most Recent Events
- 27 Nov 2023 Preclinical trials in Renal transplant rejection in USA (IV) before November 2023 (Hillhurst pipeline, November 2023)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Delayed-graft-function in USA (PO)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Brain injuries in USA (PO)